| pubmed-article:11417762 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11417762 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:11417762 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11417762 | lifeskim:mentions | umls-concept:C0028621 | lld:lifeskim |
| pubmed-article:11417762 | lifeskim:mentions | umls-concept:C0376637 | lld:lifeskim |
| pubmed-article:11417762 | lifeskim:mentions | umls-concept:C0205173 | lld:lifeskim |
| pubmed-article:11417762 | lifeskim:mentions | umls-concept:C0282440 | lld:lifeskim |
| pubmed-article:11417762 | lifeskim:mentions | umls-concept:C1096777 | lld:lifeskim |
| pubmed-article:11417762 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:11417762 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11417762 | pubmed:dateCreated | 2001-6-21 | lld:pubmed |
| pubmed-article:11417762 | pubmed:abstractText | To assess the durability of the antiretroviral effect in plasma and cerebrospinal fluid (CSF) of antiviral therapy intensification, produced by the addition of indinavir from week 12 onwards to the original regimen of zidovudine/lamivudine or stavudine/lamivudine, after 72 weeks of follow-up using an ultrasensitive HIV-1 RNA assay. To assess CSF concentrations of indinavir at week 48. | lld:pubmed |
| pubmed-article:11417762 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11417762 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417762 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11417762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417762 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11417762 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:11417762 | pubmed:issn | 1359-6535 | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:ReissPP | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:de WolfFF | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:MaasJJ | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:RoseM BMB | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:LangeJ MJM | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:WeverlingG... | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:PortegiesPP | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:MiedemaFF | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:BurgerD MDM | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:JurriaansSS | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:FoudraineN... | lld:pubmed |
| pubmed-article:11417762 | pubmed:author | pubmed-author:HoetelmansR... | lld:pubmed |
| pubmed-article:11417762 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11417762 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:11417762 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11417762 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11417762 | pubmed:pagination | 55-62 | lld:pubmed |
| pubmed-article:11417762 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:meshHeading | pubmed-meshheading:11417762... | lld:pubmed |
| pubmed-article:11417762 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11417762 | pubmed:articleTitle | Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial. | lld:pubmed |
| pubmed-article:11417762 | pubmed:affiliation | Municipal Health Service, Department of Public Health and Environment, Amsterdam, The Netherlands. foudraine.verhoef@net.hcc.nl | lld:pubmed |
| pubmed-article:11417762 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11417762 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11417762 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11417762 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
